The pharmacokinetics of intravenously administered N-formimidoyl thienamycin (MK0787) were studied in 14 healthy male subjects in a single-dose study, in which the volunteers received N-formimidoyl thienamycin with and without probenecid, and in a multiple-dose study, in which the subjects were given 250 or 500 mg every 8 h for 10 doses. High dose-related plasma concentrations of Nformimidoyl thienamycin were achieved; co-administration with probenecid resulted in only minor increases in these concentrations. No accumulation in plasma was seen after multiple doses. The plasma half-life of N-formimidoyl thienamycin was slightly less than 1 h and did not increase significantly with the coadministration of probenecid. The urinary recovery of N-formimidoyl thienamycin varied between 6.0 and 38.4% of the dose with a marked intersubject variability. Variations in individual subjects were small, however, when the urinary recoveries after repeated doses were compared. These results were in agreement with previous animal studies showing a renal metabolism of Nformimidoyl thienamycin. Probenecid administration resulted in a marked decrease in N-formimidoyl thienamycin urinary recovery. In vitro experiments showed that the decay of N-formimidoyl thienamycin in spiked pretreatment urine samples was 2 to 5%/h with more rapid degradation at acidic than at basic pH. N-Formimidoyl thienamycin (MK0787) is a stable derivative of thienamycin, a carbapenem antibiotic produced by Streptomyces cattleya (5). Its antibacterial spectrum is unusually broad and includes many commonly antibiotic-resistant bacterial species, e.g., Pseudomonas aeruginosa and enterococci (2, 3, 9). The antibacterial activity is bactericidal, and N-formimidoyl thienamycin is extremely resistant to degradation by bacterial P-lactamases (1, 8) .
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In animals, N-formimidoyl thienamycin is rapidly excreted via the kidneys (3). However, urinary recovery varies with the species, and a renal metabolism of N-formimidoyl thienamycin has been demonstrated. The present studies were undertaken to investigate the pharmacokinetics of N-formimidoyl thienamycin in healthy volunteers after the administration of single doses (with or without the prior administration of probenecid) and after multiple doses.
(These studies were presented at the 21st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, 111., 1981.) MATERIALS AND METHODS Subjects. Fourteen healthy male Caucasian subjects were recruited for the two studies. The mean age was 22 years (range, 19 to 28 years), and the mean body weight was 71.6 kg (range, 62.3 to 77.4 kg). Written informed consent was obtained, and the studies were approved by the Ethical Committee at the Faculty of Medicine, University of Gothenburg.
Single-dose study. The single-dose study was an open, randomized, three-way crossover trial of 12 subjects who received three single doses of 250 mg of N-formimidoyl thienamycin (Merck, Sharp & Dohme Research Laboratories, Rahway, N.J.). One of the doses was preceded by 2 creatinine was determined in each of these portions. Safety tests were performed before and after each test dose and included hemoglobin, hematocrit, total and differential white blood cell count, platelet estimate, blood urea nitrogen, serum aspartate, and alanine aminotransferases, alkaline phosphatases, total bilirubin, serum creatinine, fasting blood sugar, total serum protein, urine osmolality, urine pH, urine protein, and sugar and urine microscopy. In addition, pulse rate, blood pressure, and respiration rate were measured before, immediately after, and 30 min after the infusions.
Mulpledse study. Six subjects, five of whom participated in the single-dose study, received 10 doses each of 250 mg (two subjects) or 500 mg (four subjects) of N-formimidoyl thienamycin. Each dose was administered as a constant-rate intravenous infusion over 20 min with N-formimidoyl thienamycin in 100 ml of physiological saline. In connection with the 1st, 4th, 7th, and 10th doses, blood samples were obtained before and at 20 and 30 min and at 1, 2, 4, 6, and 8 h after the initiation of the infusions. Urine was collected before and at 0-to 1-, 1-to 2-, 2-to 3-, 3-to 4-, 5-to 6-, and 6-to 8-h intervals after the beginning of the infusions. Safety tests as described above were performed before the first and after the last doses.
In vitro eprimbnts. To study the degadation of Nformimidoyl thienamycin in urine, pretreatment urine samples were spiked with N-formimidoyl thienamycin to final concentrations of 9 or 180 pg/ml and incubated in sealed tubes at 37C for 1, 2, 3, or 4 h and subsequently stabilized and frozen as described below and analyzed for N-formimidoyl thienamycin concentration.
N-Fodmnidoyl thlenamyn assys. Blood samples, which were obtained in heparinized vacutainers, were immediately centrifuged at 2 to 5C, and plasma was withdrawn. To reduce the possible degradation of Nformimidoyl thienamycin, plasma was mixed with an equal volume of a 1:1 mixture of 1 M morpholinethanesulfonate buffer (pH 6) and ethylene glycol before being frozen at -80°C. The volumes of the urine samples were determined, and samples were mixed with equal volumes of a 1:1 mixture of 1 M morpholinepropanesulfonate (MOPS) buffer (pH 6.8) and ethylene glycol before being frozen at -80°C and assayed within 8 weeks.
Plasma and urine concentrations of N-formimidoyl thienamycin were assayed with a large-plate disk diffusion technique. The medium used was brain heart infusion agar, and the test strain was Bacillus subtilis ATCC 12432. Each sample was diluted to an estimated N-formimidoyl thienamycin concentration of 1 pg/ml with 0.05 M MOPS buffer. A 25->4 sample was applied to a 6-mm paper disk, which was placed on the agar surface. Standards rangng from 0.25 to 2 pg/ml were prepared in the same way. Samples and standards were tested in triplicate. After incubation over night at 37°C, inhibition zones were measured from photographs using computerized image analysis. The technique allowed assays of N-formimidoyl thienamycin concentrations >0.25 pg/ml. The variability of the assays was not greater than 3% at a 95% confidence limit. Pharmacokinetic analyses. The area under the plasma concentration-time curve (AUC) was estimated by the spline (12) Plasma kinetics of N-formimidoyl thienamycin. The plasma concentrations obtained with single 250-mg doses of N-formimidoyl thienamycin with or without probenecid are given in Fig. 1 , in which the plasma concentrations obtained with N-formimidoyl thienamycin alone are also given for the volunteer with reduced renal function and a glomerular filtration rate of about 51 mi/mn per 1.73 m2 of body area. The plasma concentrations were similar for all volunteers, except the one with reduced renal function, who had a considerably slower elimination of Nformimidoyl thienamycin than did the others. The co-administration of N-formimidoyl thienamycin with probenecid resulted in a significant (P < 0.05, Student's t test for paired differences) increase of the plasma concentrations when the samples collected 30 min after the end of the infusions were considered. The increase varied between 1 and 20%o. Figure 2 demonstrates that repeated doses of N-formimidoyl thienamycin caused no accumulation in the plasma and that the concentrations increased proportionally to the increase in dose.
The pharmacokinetic variables showed small variations between subjects when the volunteer VOL. 23, 1983 on October 18, 2017 by guest http://aac.asm.org/ Downloaded from Stabilit of N-formnmmdoyl thienanycn. The decay of N-formimidoyl thienamycin in spiked urine was found to vary between <5 and 19%/h. In individual subjects, the decay rates were not related to the urinary recoveries of N-formimidoyl thienamycin (see below). Similar decay rates were noted in the samples spiked at 9 or 180 Sag/ml. The decay seemed to follow a firstorder kinetic time course and varied with the pH of the urine. The more acid the urine was, the more rapid was the decay. Taking into account the fact that the pretreatment urine samples always had a lower pH than did the samples collected after the administration ofthe dose and that the mean exposure time of N-formimidoyl thienamycin after renal excretion was 30 min, we estimated that the hourly degradation of Nformimidoyl thienamycin in the urine was 2 to 5% at 370C. Urine excretion of N-formimdoyl thienamycin. The urinary recovery of N-formimidoyl thienamycin varied considerably between the subjects (see Table 4 ). After a single dose of N-formimidoyl thienamycin without probenecid, the lowest urinary recovery observed was 6.0%o, and the highest urinary recovery observed was 38.4%.
The co-administration of probenecid resulted in a mean reduction of 26% in the individual urinary recoveries of N-formimidoyl thienamycin and a marked reduction in the renal clearance of the antibiotic (Table 3) .
Although there was a pronounced inter-individual variation in urinary recovery, intra-individual variability was very small in all but two of the subjects as demonstrated by the combined data of the single-and multiple-dose studies ( Table 4) .
The actual urine concentrations of N-formimidoyl thienamycin were rather low and varied considerably. That variation was due not only to different urinary recovery of N-formimidoyl thienamycin but also to large differences in urine volumes. When urine concentrations were calculated for a diuresis of 60 ml/h, a pattern more consistent with the variability in urinary recovery was obtained (Fig. 3) .
DISCUSSION
The results obtained in this study demonstrated that high dose-related plasma concentrations were achieved after the intravenous administration of single or multiple doses of N-formimidoyl thienamycin. The co-administration of probenecid resulted in only marginally increased plasma concentrations, and the effect on the half-life was minimal. This would suggest that only a beginning of N-formimidoyl minor portion of N-formimidoyl thienamycin is excreted via tubular secretion, which is in agreement with the observation that the tubular secretion of N-formimidoyl thienamycin accounts for only about 20%o of renal excretion in chimpanzees (3) . Probenecid administration also resulted in about a 25% reduction in N-formimidoyl thienamycin urinary recovery. This might have been due partly to the systemic metabolism of the fraction of N-formimidoyl thienamycin excluded from tubular secretion by probenecid. It has been demonstrated in animals that both the filtered and the excreted fractions of Nformnimidoyl thienamycin are subject to metabolism by a dipeptidase, identified as dehydropeptidase I and located at the brush border of the proximal tubular cell (3). The findings in this study, including the observation that the decay of N-formimidoyl thienamycin in spiked urine was relatively slow and not correlated with urinary recovery in the subjects, were consistent with a metabolism of N-formimidoyl thienamycin similar to the one found in animals. Results presented in the accompanying manuscript demonstrate that the dehydropeptidase is, indeed, responsible for at least the major part of the renal metabolism of N-formimidoyl thienamycin in humans since the concomitant administration of N-formimidoyl thienamycin with dehydropeptidase inhibitors restored urinary recovery to about 70% of the dose and eliminated the between-subject variation of the urinary recovery (7) . Although the degree of metabolism was fairly constant between individuals in the animal studies, these results indicate a large inter-individual variability in humans. Interestingly, the within-subject variability was small, indicating that there are differences in the amount of enzyme available at the proximal tubular cells for the metabolism of N-f6rmimidoyl thienamycin.
The clinical consequence of these observations is a potential for lower or more rapidly declining concentrations of the drug in urine, especially in subjects with a high degree of metabolism. The antibacterial activity of Nformimidoyl thienamycin is characterized by minimum inhibitory concentrations normally below 1.0 pg/ml but occasionaRy increasing to 4 to 10 pg/ml for scattered strains of P. aeruginosa (4, 6, 9) . Urine concentatis of 10 */ml could be aintained for 4 formimidoyl thienamycin could be maintained would increase considerably if the renal metabolism could be controlled. Recent studies in which N-formimidoyl thienamycin was co-administered with dehydropeptidase inhibitors demonstrate that therapeutic urine concentrations can be maintained for a considerably longer period when N-formimidoyl thienamycin is administered together with such inhibitors of its renal metabolism (7) .
